Sign in
Taking people in United StatesPhase 2

Tests CXA-10 for airway tightness in obese adults with asthma

Tests CXA-10 against placebo in obese adults with asthma for airway sensitivity.

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Registry title
Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
8 Feb 2023
Expected to end
30 Jan 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CXA-10
  • Matching Placebo
Record updated
10 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for obese adults with asthma who are on regular inhaled asthma medicine. It tests a drug called CXA-10 against a placebo.

Age
18 to 65 years
Sex
Men and women can join.
Disease stage
Asthma diagnosed by a doctor more than 6 months ago, with lung function (FEV1) between 50 and 95% of predicted. Must also have a BMI of 30 or more.
Earlier treatment
Regular treatment with inhaled corticosteroids (up to 1000 mcg/day fluticasone or equivalent), long-acting beta agonists and/or long-acting muscarinic antagonists for at least 3 months, on a stable dose for the 4 weeks before Visit 0.
Biomarker or test result
Lung test response: at least 12% improvement after 4 puffs of albuterol, or PC20 methacholine (16 mg) test if the change is under 12%.

Main reasons for not taking part

  • Respiratory tract infection in the last 4 weeks
  • Oral or systemic corticosteroid burst in the last 4 weeks
  • Asthma-related hospital stay in the last 6 weeks or ER visit in the last 4 weeks
  • Three or more asthma attacks needing systemic corticosteroids in the past year
  • Current smoker, or quit within the last 1 year, or 10 pack years

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adequate completion of informed consent process with written documentation. Male and female patients, 18 to 65 years old. Female subjects should be either post-menopausal or surgically sterile, or, if child-bearing potential (WOCP) should agree to use an acceptable method of contraception, for the duration of the study, with a negative pregnancy test prior to entering the study
  • BMI >/= 30
  • Diagnosis of asthma: based on previous physician diagnosis for > 6 months, and baseline pre-bronchodilator (BD) FEV1 between 50 and 95% predicted with either a 12% or greater bronchodilator response to 4 puffs of albuterol or PC20 methacholine (16 mg) if <12% change post BD
  • Regular treatment with inhaled corticosteroids (ICS) (up to 1000 mcg/day fluticasone/equivalent), long acting beta agonists (LABA), and/or long-acting muscarinic antagonists (LAMA), which can be combination medication for at least 3 months; on a stable dose for the 4 weeks prior to Visit 0

Who cannot take part

  • Oral or systemic corticosteroid burst within the last 4 weeks
  • Three or more asthma exacerbations requiring treatment with systemic corticosteroids in the past year consistent with severe asthma
  • Asthma-related ER visit within the previous 4 weeks
  • Current smoking or have former smokers that quit within the previous 1 year, or 10 pack years
  • Respiratory tract infection within the last 4 weeks
  • Asthma-related hospitalization within the last 6 weeks

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • University of Colorado Anschutz Medical CampusAurora, United StatesContact: Asthma ResearchTaking people

About the trial

What the trial wants to find out

The main purpose of this Phase 2 double blind, placebo controlled crossover clinical study is to demonstrate the efficacy and safety of CXA-10 in obese adult asthmatics. Obesity induces a chronic systemic inflammatory state characterized by impaired adipokine signaling, pro-inflammatory cytokine responses, inflammatory cell activation and enhanced generation of oxidative inflammatory mediators. This impacts the lung, increasing the severity of asthma and its exacerbations. This research will evaluate how a synthetic nitro-fatty acid (CXA-10, 10-nitro-octadec-9-enoic acid) suppresses the systemic and airway inflammation that contributes to the obese asthmatic phenotype. Current data support the pleiotropic signaling actions of CXA-10 to induce adaptive signaling actions that beneficially modulate adipokine and cytokine expression and inhibit systemic and pulmonary inflammation. The investigators hypothesize that CXA-10 induced signaling responses will alleviate obesity-related airway hyperreactivity in obese adult asthmatics.

The 2 groups in the trial

  • CXA-10Treatment being tested

    Administered orally, continuously, and daily for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Drug will be dispensed at Visit 4.

  • Matching PlaceboPlacebo, for comparison

    Administered orally, daily, and continuously for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Placebo will be dispensed at Visit 4.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Anti Inflammatory Lipid Mediators in Asthma: A Double Blind Placebo Control Cross Over, Proof of Concept Study of CXA-10 to Reduce Bronchial Hyperresponsiveness in Obese Asthmatics; Lipid Anti-Inflammatory Mediators in Asthma to Reduce Hyperresponsiveness in Obese Asthmatics
Plain-language title
Tests CXA-10 for airway tightness in obese adults with asthmaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT03762395, who can take part
Record updated
10 June 2025